睾丸肿瘤中具有潜在临床应用价值的分子生物标志物
本文综述了睾丸生殖细胞肿瘤(TGCT)和性索间质肿瘤(SCST)的分子生物标志物研究进展,重点介绍了最具临床应用潜力的标志物。TGCT方面,发育生物学有助于识别从经典血清标志物到多能性因子及循环microRNA-371-373簇等标志物;SCST方面则聚焦于组织标志物,全基因组研究增进了对罕见表型和侵袭性行为的理解。多种新标志物正走向临床,病理医生需了解其优势与局限。
要点
- TGCT的发育生物学为识别临床有用标志物(如miR-371-373簇)提供了关键基础。
- SCST的生物标志物研究仅限于组织标志物,全基因组分析有助于理解罕见表型。
- 病理医生应了解新标志物的优势与局限,以合理应用并最大化临床获益。
核心结论
- TGCT和SCST的分子生物标志物研究取得重要进展,多种新标志物正走向临床实施。
研究设计与样本
- 本文为综述,概述了TGCT和SCST分子生物标志物的研究进展,聚焦最具临床应用潜力者。
主要发现
- TGCT中,发育生物学有助于识别从经典血清肿瘤标志物到多能性因子及循环microRNA-371-373簇的标志物。
- SCST中,研究仅聚焦于组织生物标志物,全基因组研究增进了对罕见表型和某些肿瘤侵袭性行为的理解。
临床怎么用
- 病理医生应了解新标志物的优势与局限,以合理应用并最大化临床获益。
局限性
- 某些类型睾丸肿瘤总体罕见,生物标志物研究进展相对缓慢。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Testicular germ cell tumors (TGCTs) and sex cord-stromal tumors (SCSTs) are the most common testicular neoplasms. The morphologic spectrum of such tumors is wide, with several histologic subtypes within each group. Testicular tumors often represent a diagnostic challenge, requiring proper identification of their biologic potential for accurate risk stratification and selection of therapy. In the era of precision medicine, molecular biomarkers are increasingly assuming a critical role in the management of patients with cancer. Given the overall rarity of certain types of testicular neoplasms, progress in biomarker research has been relatively slow. However, in recent years, we have witnessed a multitude of important contributions, including both tissue-based and liquid biopsy biomarkers, stemming from important discoveries of tumor pathobiology, accurate histopathological analysis, multi-institutional studies, and genome-wide molecular analyses of specific tumor subtypes. In this review, we provide an overview of the progress in molecular biomarkers of TGCTs and SCSTs, focusing on those with greatest potential for clinical application. In TGCTs, developmental biology has been the key to understanding these tumors and identifying clinically useful biomarkers (from classical serum tumor markers to pluripotency factors and circulating microRNAs of the 371-373 cluster). For SCSTs, studies have focused on tissue biomarkers only, and genome-wide investigations have recently contributed to a better understanding of rare phenotypes and the aggressive biological behavior of some tumors within this nosologic category. Several new biomarkers are moving toward clinical implementation in this field. Therefore, the practicing pathologist should be aware of their strengths and limitations in order to utilize them properly and maximize their clinical benefits.
引用
- Lobo J, Acosta AM, Netto GJ, et al. Molecular Biomarkers With Potential Clinical Application in Testicular Cancer. Mod Pathol. 2023. PMID: 37611872. doi:10.1016/j.modpat.2023.100307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。